HOME >> MEDICINE >> NEWS
VELCADE (Bortezomib) receives European marketing authorisation

Brussels, Belgium, {27 April 2004} Ortho Biotech, the biopharmaceutical division of Janssen-Cilag, today announced that the European Commission has issued a positive decision for VELCADE, a new treatment for multiple myeloma, a form of blood cancer. The novel drug is indicated to treat multiple myeloma patients who have received at least two prior therapies and demonstrated disease progression on their last therapy.

VELCADE is a completely new approach to treating multiple myeloma that acts on a unique target in cells called the proteasome.

Multiple myeloma is the second most common blood cancer, representing approximately one percent of all cancers and two percent of all cancer deaths. Worldwide in 2000, there were 73,943 cases of multiple myeloma and 57,370 deaths. In Europe there were approximately 19,000 cases in 2000 and just under 15,000 deaths (1). Only 30 percent of multiple myeloma patients survive longer than five years (2).

"The approval of VELCADE by the European Agency for the Evaluation of Medicinal Products (EMEA) represents a breakthrough in our continued battle against multiple myeloma" said Professor Mario Boccadoro, Professor of Hematology, Director of the Section of Hematology, University of Torino, Italy. "With its new and unique mechanism of action, VELCADE represents a new treatment option for patients".

Clinical results from a phase II study have shown that VELCADE can slow, reverse or halt progression of disease in patients who failed on two or more treatments, potentially helping patients live longer. In a study of 202 patients with relapsed and refractory multiple myeloma and who progressed after initial treatments, 35% responded to VELCADE and 10% had a complete remission. This pivotal study was the basis for an accelerated review of VELCADE by U.S. Food and Drug Administration (FDA) and approval within four months of the New Drug Application submission on 13 May 2003.

"We are deli
'"/>

Contact: Eva Reynolds
eva_reynolds@uk.bm.com
44-20-7831-6262
Burson-Marsteller
28-Apr-2004


Page: 1 2 3

Related medicine news :

1. VELCADE(TM) data confirms long-term survival
2. UIC professor receives international humanitarian award
3. Mailman School of Public Health receives Manhattan Tobacco Cessation Center grant
4. Epidemiologist Trichopoulos receives $5.8 million Department of Defense Innovator Award
5. GlaxoSmithKline receives unanimous favorable recommendation by FDA Advisory Committee for Boostrix
6. NYU Child Study Center receives grant from the American Red Cross September 11 recovery program
7. Northwestern Memorial Hospital receives $10 million commitment to support preeminent heart program
8. American Academy of Neurology program receives Grassroots Award
9. Orqis receives FDA approval to expand clinical trial of Cancion CRS therapy to 40 centers
10. Mayo Clinic Cancer Center receives SPORE grant for brain cancer research from NCI
11. Pfizers antifungal medicine VFEND receives FDA approval

Post Your Comments:
(Date:7/29/2014)... Alto, CA (PRWEB) July 29, 2014 ... and well-being in older adults. Once again, the non-profit agency ... Celebration, a free event for seniors. , This event gives ... active and maintain better health. There will be a variety ... and dancing, wellness vendors, tech demonstrations and artists. In addition, ...
(Date:7/29/2014)... Medicine researchers have made an important advancement toward ... deadly tick-transmitted disease, human granulocytic anaplasmosis (HGA). , ... a steady rise in the incidence of human ... the need for a vaccine critical. Successful vaccine ... prevent disease, and the VCU team has identified ...
(Date:7/29/2014)... Child abuse law firm Steinger, Iscoe & Greene ... scholarship will help future lawyers who want to fight for ... Iscoe and Greene lawyers work continuously to help victims recover ... the same. More than 6 million children are abused in ... Childhelp (retrieved 7/22/2014). , “This is an issue that’s ...
(Date:7/29/2014)... July 29, 2014 As testosterone treatment ... courts, Bernstein Liebhard LLP notes that a new study ... with Type 2 diabetes. The research, which was published ... on June 30th, involved 88 men who suffered from ... moderate aging male symptoms and erectile dysfunction. Roughly half ...
(Date:7/29/2014)... Society of America (GSA) the nation,s largest ... has chosen Barbara J. Bowers, PhD, RN, FAAN, of ... the Task Force on Minority Issues in Gerontology Outstanding ... to an individual who has exemplified outstanding commitment and ... aging. , The award presentation will take place at ...
Breaking Medicine News(10 mins):Health News:Avenidas Hosts Third Annual Successful Aging Celebration 2Health News:Researchers take steps toward development of a vaccine against tick-transmitted disease 2Health News:Researchers take steps toward development of a vaccine against tick-transmitted disease 3Health News:Steinger, Iscoe & Greene Offers Child Advocate Scholarship 2Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 2Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 3Health News:As Testosterone Lawsuits Mount, Bernstein Liebhard LLP Notes New Study Questioning Effectiveness of Low Testosterone Therapy in Diabetics 4Health News:Bowers to receive GSA's 2014 Minority Mentorship Award 2
(Date:7/29/2014)... -- Numotion,s Board of Directors has announced that as of ... company,s new Chief Executive Officer. Swinford joins ... he worked primarily for GE Healthcare Services, running businesses ranging ... His most recent position was as President and CEO of ... to join Numotion," said Mike Swinford . "I look ...
(Date:7/29/2014)... 2014 McGraw-Hill Education Professional, a leading global ... and medical communities, has announced the launch of the ... of the world-renowned medical education platform. ... , available for download onto all iOS and Android ... gain access to valuable AccessMedicine diagnostic resources ...
(Date:7/29/2014)... 29, 2014  Neurocrine Biosciences, Inc. (Nasdaq: ... its second quarter 2014 financial results after the Nasdaq ... then host a live conference call and webcast to ... Thursday morning, August 7, 2014 at 8:00 a.m. Eastern ... access the live conference call by dialing 866-952-1907 (US) ...
Breaking Medicine Technology:Numotion Names Mike Swinford CEO 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 2McGraw-Hill Education Professional's AccessMedicine App Delivers Instant Access to Essential Diagnostic Tools 3Neurocrine Biosciences Announces Conference Call And Webcast To Report Second Quarter 2014 Financial Results 2
Cached News: